TACE联合索拉非尼治疗肝细胞癌的临床观察

Primary study of TACE combined with sorafenib in hepatocellular carcinoma

目的探讨TACE联合索拉非尼治疗肝细胞癌的疗效及安全性。方法回顾性分析我院口服索拉非尼3个月以上,并行TACE的13例肝细胞癌患者,计算其生存率、治疗间隔、毒副反应及疾病进展时间。结果全组平均存活时间36.6个月,3例患者达到PR,4例SD,6例PD,临床受益率为54%。口服索拉非尼前,平均TACE间隔时间为67天;口服索拉非尼后,平均间隔103天。全组3级高血压及手足皮肤反应各3例,余7例患者未发生其他3级以上毒副反应。全组平均疾病进展时间为210天。发生3级毒副反应的患者平均疾病进展时间为313天,未发生3级以上毒副反应的患者平均疾病进展时间为122天(P=0.053)。结论TACE与索拉非尼联合治疗晚期肝细胞癌是安全、有效的。

Objective To investigate the efficacy and safety of TACE combined sorafenib in hepatocellular carcinoma.Methods A retrospective analysis of 13 hepatocellular carcinoma patients who had been treated by TACE and had been oraled sorafenib for more than three months and evaluated their survival rate,TACE interval,toxicity and TTP.Results The average survival time of the whole group was 36.6 months.Three patients achieved PR,4 patients were SD,6 patients were PD,CBR was 54%.The interval of TACE on average before oral sorafenib was 67 days.The interval after oral sorafenib was 103 days.There were three cases for grade 3 hypertension and hand-foot skin reaction respectively.The other 7 patients had not occurred above grade 3 toxicity.The average TTP of the whole group was 210 days.The average TTP of patients occurred grade 3 toxicity was 313 days and that of the other was 122 days.But there was not significant difference between them（P=0.053）.Conclusion TACE combined with sorafenib is safe and effective for patients with advanced hepatocellular carcinoma.